About Phagenesis
Phagenesis is a company based in Manchester (United Kingdom) founded in 2007 by Chad Hoskins and Conor Mulrooney was acquired by Nestle in September 2016.. Phagenesis has raised $62.08 million across 4 funding rounds from investors including Nestlé, EQT and Northern Gritstone. Phagenesis offers products and services including Phagenyx® Neurostimulation System. Phagenesis operates in a competitive market with competitors including Accelerated Care Plus, Swallow Solutions, Rymo Medical, Eswallow USA and Innovative Neurotronics, among others.
- Headquarter Manchester, United Kingdom
- Founders Chad Hoskins, Conor Mulrooney
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Phagenesis Limited
- Date of Incorporation 10 Jul, 2007
- Jurisdiction LEDBURY
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Phagenesis
Phagenesis offers a comprehensive portfolio of products and services, including Phagenyx® Neurostimulation System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Delivers electrical stimulation to treat swallowing disorders effectively.
Unlock access to complete
Funding Insights of Phagenesis
Phagenesis has successfully raised a total of $62.08M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $42 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $42.0M
-
First Round
First Round
(01 Sep 2010)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series D - Phagenesis | Valuation | Sectoral , EQT | |
| May, 2013 | Amount | Series B - Phagenesis | Valuation |
investors |
|
| May, 2012 | Amount | Grant - Phagenesis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Phagenesis
Phagenesis has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Nestlé, EQT and Northern Gritstone. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sectoral Asset Management is focused on global healthcare investment.
|
Founded Year | Domain | Location | |
|
Venture capital co-investments are made in UK later-stage businesses.
|
Founded Year | Domain | Location | |
|
Investment firm focused on investing in science and technology firms
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Phagenesis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Phagenesis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Phagenesis Comparisons
Competitors of Phagenesis
Phagenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accelerated Care Plus, Swallow Solutions, Rymo Medical, Eswallow USA and Innovative Neurotronics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
FDA-cleared devices for dysphagia treatment are developed and provided.
|
|
| domain | founded_year | HQ Location |
Devices for diagnosing and treating dysphagia through oropharyngeal strengthening
|
|
| domain | founded_year | HQ Location |
Provides therapy solutions for individuals with swallowing difficulties.
|
|
| domain | founded_year | HQ Location |
Develops neuromuscular stimulation devices for the treatment of dysphagia.
|
|
| domain | founded_year | HQ Location |
Develops therapeutic devices for neuro-rehabilitation to aid patient recovery.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Phagenesis
Frequently Asked Questions about Phagenesis
When was Phagenesis founded?
Phagenesis was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Where is Phagenesis located?
Phagenesis is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Who is the current CEO of Phagenesis?
Chad Hoskins is the current CEO of Phagenesis. They have also founded this company.
Is Phagenesis a funded company?
Phagenesis is a funded company, having raised a total of $62.08M across 4 funding rounds to date. The company's 1st funding round was a Grant of $1.58M, raised on Sep 01, 2010.
What does Phagenesis do?
Phagenesis was founded in 2007 in Manchester, United Kingdom, and operates within the medical devices sector. Focus is placed on addressing neurogenic dysphagia through innovative technologies. The Phagenyx System has been created, employing Pharyngeal Electrical Stimulation to restore swallowing control, improve airway protection, and support patient recovery processes. Operations center on device development and clinical applications in neurology-related care.
Who are the top competitors of Phagenesis?
Phagenesis's top competitors include Accelerated Care Plus, Swallow Solutions and Rymo Medical.
What products or services does Phagenesis offer?
Phagenesis offers Phagenyx® Neurostimulation System.
Who are Phagenesis's investors?
Phagenesis has 8 investors. Key investors include Nestlé, EQT, Northern Gritstone, Sectoral Asset Management, and British Patient Capital.